Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gimsing

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|November 29, 2018
Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort studyRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 7, 2003
99mTc-aprotinin scintigraphy in amyloidosisBente K Schaadt, Helle W Hendel, Peter Gimsing, et al.
Leukemia & Lymphoma|February 24, 2009
Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myelomaTina Damgaard, Lene M Knudsen, Inger Marie S Dahl, et al.
Biomarkers in Medicine|July 16, 2015
N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myelomaAnne K Mylin, Jens P Goetze, Lene Heickendorff, et al.
International Journal of Cancer|December 6, 2011
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myelomaNiels F Andersen, Ulla Vogel, Tobias W Klausen, et al.
Haematologica|September 8, 2009
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportAnnette J Vangsted, Tobias W Klausen, Peter Gimsing, et al.
European Journal of Haematology|June 24, 2014
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survivalNiels F Andersen, Ulla Vogel, Tobias W Klausen, et al.
Leukemia & Lymphoma|May 3, 2018
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myelomaKonstantinos Dimopoulos, Helga Fibiger Munch-Petersen, Christian Winther Eskelund, et al.
European Journal of Haematology|May 31, 2008
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaPeter Gimsing, Mads Hansen, Lene M Knudsen, et al.
Leukemia & Lymphoma|January 10, 2015
Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myelomaAnne K Mylin, Niels Abildgaard, Julia S Johansen, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|November 29, 2018
Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort studyRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 7, 2003
99mTc-aprotinin scintigraphy in amyloidosisBente K Schaadt, Helle W Hendel, Peter Gimsing, et al.
Leukemia & Lymphoma|February 24, 2009
Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myelomaTina Damgaard, Lene M Knudsen, Inger Marie S Dahl, et al.
Biomarkers in Medicine|July 16, 2015
N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myelomaAnne K Mylin, Jens P Goetze, Lene Heickendorff, et al.
International Journal of Cancer|December 6, 2011
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myelomaNiels F Andersen, Ulla Vogel, Tobias W Klausen, et al.
Haematologica|September 8, 2009
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportAnnette J Vangsted, Tobias W Klausen, Peter Gimsing, et al.
European Journal of Haematology|June 24, 2014
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survivalNiels F Andersen, Ulla Vogel, Tobias W Klausen, et al.
Leukemia & Lymphoma|May 3, 2018
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myelomaKonstantinos Dimopoulos, Helga Fibiger Munch-Petersen, Christian Winther Eskelund, et al.
European Journal of Haematology|May 31, 2008
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaPeter Gimsing, Mads Hansen, Lene M Knudsen, et al.
Leukemia & Lymphoma|January 10, 2015
Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myelomaAnne K Mylin, Niels Abildgaard, Julia S Johansen, et al.
Pageof 6